Table I.
Association between expression of Plk2 and clinical variables in colorectal cancer.
| Variable | Parameter | All, n (%) | Expression of Plk
|
P-value | |
|---|---|---|---|---|---|
| Low, n (%) | High, n (%) | ||||
| Sex | 0.447 | ||||
| Female | 256 (45.2) | 123 (43.5) | 133 (47) | ||
| Male | 310 (54.8) | 160 (56.5) | 150 (53) | ||
| Age | 0.064 | ||||
| <70 years | 301 (53.2) | 162 (57.2) | 139 (49.1) | ||
| ≥70 years | 265 (46.8) | 121 (42.8) | 144 (50.9) | ||
| Tumor location | 3.95×10−7 | ||||
| Distal | 342 (60.4) | 201 (71) | 141 (49.8) | ||
| Proximal | 224 (39.6) | 82 (29) | 142 (50.2) | ||
| Stage | 0.301 | ||||
| CIS | 4 (0.7) | 4 (1.4) | 0 (0) | ||
| I | 37 (6.5) | 20 (7.1) | 17 (6) | ||
| II | 258 (45.6) | 128 (45.2) | 130 (45.9) | ||
| III | 203 (35.9) | 104 (36.7) | 99 (35) | ||
| IV | 61 (10.8) | 27 (9.5) | 34 (12) | ||
| NA | 3 (0.5) | 0 (0) | 3 (1.1) | ||
| MMR status | 1.01×10−8 | ||||
| dMMR | 75 (13.3) | 15 (5.3) | 60 (21.2) | ||
| pMMR | 444 (78.4) | 251 (88.7) | 193 (68.2) | ||
| NA | 47 (8.3) | 17 (6) | 30 (10.6) | ||
| TP53 status | 3.87×10−7 | ||||
| Wt | 161 (28.4) | 57 (20.1) | 104 (36.7) | ||
| Mut | 190 (33.6) | 120 (42.4) | 70 (24.7) | ||
| NA | 215 (38) | 106 (37.5) | 109 (38.5) | ||
| KRAS status | 0.003 | ||||
| Wt | 328 (58) | 182 (64.3) | 146 (51.6) | ||
| Mut | 217 (38.3) | 91 (32.2) | 126 (44.5) | ||
| NA | 21 (3.7) | 10 (3.5) | 11 (3.9) | ||
| BRAF status | 5.24×10−7 | ||||
| Wt | 461 (81.4) | 248 (87.6) | 213 (75.3) | ||
| Mut | 51 (9) | 8 (2.8) | 43 (15.2) | ||
| NA | 54 (9.5) | 27 (9.5) | 27 (9.5) | ||
| Adj.Chem. | 0.185 | ||||
| No | 316 (55.8) | 153 (54.1) | 163 (57.6) | ||
| Yes | 233 (41.2) | 127 (44.9) | 106 (37.5) | ||
| NA | 17 (3) | 3 (1.1) | 14 (4.9) | ||
Plk2, polo-like kinase 2; MMR, mismatch repair; dMMR, deficient MMR; pMMR, proficient MMR; Wt, wild-type; Mut, mutation; KRAS, Kirsten rat sarcoma viral oncogene homolog; BRAF, B raf serine/threonine kinase proto oncogene; TP53, tumor protein 53; Adj.Chem., adjuvant chemotherapy; NA, not available.